Detalhe da pesquisa
1.
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Prostate
; 75(15): 1790-801, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26332453